Compare · ILMN vs SERA
ILMN vs SERA
Side-by-side comparison of Illumina Inc. (ILMN) and Sera Prognostics Inc. (SERA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and SERA operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $41.04B, about 502.5x SERA ($81.7M).
- Over the past year, ILMN is up 188.3% and SERA is down 34.8% - ILMN leads by 223.1 points.
- ILMN has been more active in the news (8 items in the past 4 weeks vs 1 for SERA).
- ILMN has more recent analyst coverage (25 ratings vs 8 for SERA).
- Company
- Illumina Inc.
- Sera Prognostics Inc.
- Price
- $268.05-1.39%
- $2.04-0.97%
- Market cap
- $41.04B
- $81.7M
- 1M return
- +17.04%
- +0.99%
- 1Y return
- +188.29%
- -34.82%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 2021
- News (4w)
- 8
- 1
- Recent ratings
- 25
- 8
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Sera Prognostics Inc.
Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Latest ILMN
- Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
- SEC Form 8-K filed by Illumina Inc.
- Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Illumina releases SpliceAI2 to help advance rare disease research
- SEC Form 4 filed by Illumina Inc.
- SEC Form SCHEDULE 13G filed by Illumina Inc.
- Director Meister Keith A. was granted 107 shares, increasing direct ownership by 2% to 6,887 units (SEC Form 4)
- Director Ullem Scott B. was granted 113 shares, increasing direct ownership by 1% to 11,143 units (SEC Form 4)
- Chief Legal Officer Coletti Julie Ann was granted 18,763 shares (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.99% to 40,927 units (SEC Form 4)
Latest SERA
- SEC Form 4 filed by Sera Prognostics Inc.
- Chief Executive Officer Lindgardt Zhenya sold $14,044 worth of shares (7,022 units at $2.00), decreasing direct ownership by 0.83% to 837,848 units (SEC Form 4) to satisfy withholding tax
- General Counsel Jackson Benjamin sold $4,380 worth of shares (2,190 units at $2.00), decreasing direct ownership by 1% to 159,566 units (SEC Form 4) to satisfy withholding tax
- Chief Commercial Officer Anderson Dyaarl Lee Jr. sold $3,600 worth of shares (1,800 units at $2.00), decreasing direct ownership by 2% to 76,198 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Inglis Tiffany Eul Davis sold $972 worth of shares (486 units at $2.00), decreasing direct ownership by 0.53% to 91,589 units (SEC Form 4) to satisfy withholding obligation
- Chief Executive Officer Lindgardt Zhenya sold $40,278 worth of shares (20,139 units at $2.00), decreasing direct ownership by 2% to 844,870 units (SEC Form 4) (for withholding tax)
- SEC Form 4 filed by Chief Financial Officer Aerts Austin
- SEC Form 3 filed by new insider Gleason Scott
- Chief Financial Officer Gleason Scott was granted 117,924 shares (SEC Form 4)
- 1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.